11/27
01:29 am
nuvl
Does Nuvalent's Recent Trial Success Justify the Stock's 36% 2025 Rally? [Yahoo! Finance]
Low
Report
Does Nuvalent's Recent Trial Success Justify the Stock's 36% 2025 Rally? [Yahoo! Finance]
11/26
06:43 am
nuvl
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
06:30 am
nuvl
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/24
04:01 pm
nuvl
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Low
Report
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
11/24
09:04 am
nuvl
Nuvalent (NASDAQ:NUVL) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Nuvalent (NASDAQ:NUVL) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
nuvl
Nuvalent (NASDAQ:NUVL) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/19
04:45 pm
nuvl
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC [Yahoo! Finance]
Low
Report
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC [Yahoo! Finance]
11/19
04:19 pm
nuvl
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Low
Report
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
11/18
11:50 pm
nuvl
Nuvalent Announces Pricing of Public Offering of Common Stock
Low
Report
Nuvalent Announces Pricing of Public Offering of Common Stock
11/18
01:13 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $120.00 to $135.00. They now have a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $120.00 to $135.00. They now have a "buy" rating on the stock.
11/18
11:04 am
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Robert W. Baird from $112.00 to $158.00. They now have an "outperform" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Robert W. Baird from $112.00 to $158.00. They now have an "outperform" rating on the stock.
11/18
10:00 am
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Guggenheim from $125.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Guggenheim from $125.00 to $155.00. They now have a "buy" rating on the stock.
11/18
06:38 am
nuvl
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate [Yahoo! Finance]
Low
Report
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate [Yahoo! Finance]
11/18
02:25 am
nuvl
Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript [Seeking Alpha]
Low
Report
Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript [Seeking Alpha]
11/17
09:32 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $125.00 price target on the stock, up previously from $120.00.
Medium
Report
Nuvalent (NASDAQ:NUVL) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $125.00 price target on the stock, up previously from $120.00.
11/17
05:04 pm
nuvl
Nuvalent (NASDAQ:NUVL) was given a new $152.00 price target on by analysts at Barclays PLC.
Low
Report
Nuvalent (NASDAQ:NUVL) was given a new $152.00 price target on by analysts at Barclays PLC.
11/17
04:35 pm
nuvl
Nuvalent Announces Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Nuvalent Announces Public Offering of Common Stock [Yahoo! Finance]
11/17
04:16 pm
nuvl
Nuvalent announces public offering of common stock [Seeking Alpha]
Low
Report
Nuvalent announces public offering of common stock [Seeking Alpha]
11/17
04:01 pm
nuvl
Nuvalent Announces Public Offering of Common Stock
Low
Report
Nuvalent Announces Public Offering of Common Stock
11/17
12:58 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $135.00. They now have a "buy" rating on the stock.
Low
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $135.00. They now have a "buy" rating on the stock.
11/17
12:37 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Leerink Partners from $140.00 to $149.00. They now have an "outperform" rating on the stock.
Medium
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at Leerink Partners from $140.00 to $149.00. They now have an "outperform" rating on the stock.
11/17
12:01 pm
nuvl
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at HC Wainwright from $130.00 to $155.00. They now have a "buy" rating on the stock.
Medium
Report
Nuvalent (NASDAQ:NUVL) had its price target raised by analysts at HC Wainwright from $130.00 to $155.00. They now have a "buy" rating on the stock.
11/17
06:43 am
nuvl
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC [Yahoo! Finance]
Medium
Report
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC [Yahoo! Finance]
11/17
06:30 am
nuvl
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Medium
Report
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
11/15
07:05 pm
nuvl
Nuvalent (NUVL): A Closer Look at Valuation as New ALK Inhibitor Data Presentation Approaches [Yahoo! Finance]
Medium
Report
Nuvalent (NUVL): A Closer Look at Valuation as New ALK Inhibitor Data Presentation Approaches [Yahoo! Finance]